Avatao Biotech | GenomeWeb

Avatao Biotech

NEW YORK (GenomeWeb News) – Rosetta Genomics has terminated a licensing deal with Chinese diagnostic firm Avatao Biotech, the Israeli molecular diagnostic firm disclosed in a document filed with the US Securities and Exchange Commission on Monday.

NEW YORK (GenomeWeb News) – Rosetta Genomics said today it is terminating a licensing deal with Avatao Biotech, accusing the Chinese diagnostic firm of material breach of an agreement.

Rosetta Genomics this week announced that it has signed a definitive agreement to sell $1.9 million in stock and warrants in a private placement.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.